Mereo BioPharma FY2025 net loss $41.9M; setrusumab Phase 3 studies miss primary endpoints, show BMD gains

Mereo BioPharma Group plc

Cash $41.0M as of Dec 31, 2025; expected runway into mid-2027 (from $69.8M end 2024).
Setrusumab Phase 3 Orbit & Cosmic missed primary endpoint (annualized clinical fracture rate) but achieved high statistical significance on BMD improvement.
Setrusumab showed vertebral fracture reductions and statistically significant PRO improvements in pain/daily activity in pediatric patients.
Alvelestat site feasibility for Phase 3 in AATD-LD complete; partnering discussions ongoing; Phase 2b in bronchiectasis designed.
Vantictumab outlicensed to āshibio; Phase 2 in osteopetrosis planned H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Mereo BioPharma Group plc reported financial results for the full year ended December 31, 2025.

Period: the full year ended December 31, 2025
Result: reported results

Exact text from the filing

Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the full year ended December 31, 2025, and provided an update on recent corporate developments.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Mereo BioPharma Group plc filing history →

Source: SEC EDGAR

accession 0001193125-26-115211

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.